Safety and PK of Repeated Doses of IRL201104 in Healthy Volunteers

Inclusion Criteria: * Healthy male and female subjects age 18 to 65 years of age, and in good health as determined by medical history, physical examination, vital signs, electrocardiogram, and laboratory tests. * Female subjects agree to use highly effective contraception or be of non-childbearing potential. * Written informed consent must be obtained before any assessment is performed. * Able to communicate well with the Investigator/designee. Exclusion Criteria: * Any known reaction to study drug or components * concurrent or recent infection or clinically significant conditions that may place subject at risk or interference with absorption, distribution or excretion of drugs * No QTcF interval ≥450 milliseconds, no QRS complex ≥120 milliseconds, at Screening * Positive test results for hepatitis B surface antigen (HBsAg), hepatitis C virus antibodies (HCVAb) or human immunodeficiency virus (HIV) 1 and/or -2 antibodies at Screening. * Excessive use of caffeine-containing beverages * Urinary cotinine level indicative of smoking or history or regular use of tobacco- or nicotine containing products within 6 months before screening. * Presence or history of drug of alcohol abuse. * Positive screen for drugs-of-abuse or cotinine. * Blood donation in excess of 500mL within 3 months. * Participation in another clinical study with licensed or unlicensed study drug within 3 months of first IMP administration. * Exposure to more than 4 new chemical entities within 12 months before the first IMP administration. * Use of live vaccine 28 days before dosing with study drug until telephone follow-up and use of killed vaccine (including COVID-19 vaccine) 14 days before dosing with study drug until telephone follow-up.